Skip to content
lifestyle.nextmentors.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Thryv Therapeutics Inc.
Thryv Therapeutics to Participate in the UBS Global Biopharma Conference in London
November 12, 2026
Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome
November 3, 2026
Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure
September 15, 2026
Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain’s CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
September 3, 2026